Insulin resistance and inflammation in hypogonadotropic hypogonadism
In this placebo-controlled trial, men with type 2 diabetes and hypogonadotropic hypogonadism received testosterone or placebo for six months. Insulin sensitivity was measured directly with a euglycaemic clamp rather than inferred from symptoms.
Focus
Insulin sensitivity
Published finding
32%
Source
10.2337/dc15-1518
Record
Ref 04
Structured abstract
Method
In this placebo-controlled trial, men with type 2 diabetes and hypogonadotropic hypogonadism received testosterone or placebo for six months. Insulin sensitivity was measured directly with a euglycaemic clamp rather than inferred from symptoms.
Result
Insulin-stimulated glucose disposal improved by approximately 32%. Subcutaneous fat mass and inflammatory markers decreased. HbA1c did not significantly change during the six-month study window.
What to take with you
A euglycaemic clamp measured what the tissue did. Insulin-stimulated disposal rose about 32% on testosterone versus placebo.
Why it matters
Insulin-stimulated glucose disposal rose about 32% on testosterone versus placebo in a euglycaemic clamp.
Study frame
Insulin sensitivity
In this placebo-controlled trial, men with type 2 diabetes and hypogonadotropic hypogonadism received testosterone or placebo for six months. Insulin sensitivity was measured directly with a euglycaemic clamp rather than inferred from symptoms.
Finding
Insulin-stimulated glucose disposal improved by approximately 32%.
Contrast
Subcutaneous fat mass and inflammatory markers decreased.
Context
HbA1c did not significantly change during the six-month study window.
DOI
10.2337/dc15-1518
Category
Insulin sensitivity
Findings listed
3
Type
As published
What to take from the numbers
Boxes below use only wording already in the published summary for this study.
Reported finding
32%
Insulin-stimulated glucose disposal improved by approximately 32%.
Reported finding
2
Subcutaneous fat mass and inflammatory markers decreased.
Reported finding
1
HbA1c did not significantly change during the six-month study window.
The sample and treatment period were limited; improved insulin sensitivity is not the same as diabetes remission.
Why it matters when reading your own result
Pulled from the study's own findings.
Insulin-stimulated glucose disposal improved by approximately 32%.
Insulin sensitivity
Subcutaneous fat mass and inflammatory markers decreased.
Insulin sensitivity
HbA1c did not significantly change during the six-month study window.
Insulin sensitivity
Clinical reading
How to use this page
In this placebo-controlled trial, men with type 2 diabetes and hypogonadotropic hypogonadism received testosterone or placebo for six months. Insulin sensitivity was measured directly with a euglycaemic clamp rather than inferred from symptoms.
Your own numbers
Measure before you decide what this page means for you.
The figures here describe men who were actually measured.
- Total testosterone and SHBG
- Symptoms written down
- Haematocrit as a safety baseline
- Repeat labs before any protocol change